Patent US5246941A successfully refreshed from Google Patents.
US5246941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the treatment of depression
Assignee: Glaxo Group Ltd
•
Filing: 1993-01-15
•
Granted: 1993-09-21
•
Expires: 2013-01-15
Abstract
Abstract The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT 3 receptors for the treatment of depression.
Inventors
- 👤 Michael B. Tyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/435; A61K31/44; A61K31/445; A61K31/46; A61K31/495; A61K31/50; A61K31/55
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
40 words
A method for the treatment of depression which comprises administering to a patient suffering from depression an effective amount of endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3,3-dimethylindole-1-carboxamide, or a physiologically acceptable salt or solvate thereof, which compound acts as a 5-HT antagonist at 5-HT 3 receptors.
Claim 2
Independent Claim
40 words
A method for the treatment of depression which comprises administering to a patient suffering from depression an effective amount of endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3,3-dimethylindole-1-carboxamide, or a physiologically acceptable salt or solvate thereof, which compound acts as a 5-HT antagonist at 5-HT 3 receptors.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-09-20 | 1997-03-22 | 1997-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-09-20 | 2001-03-22 | 2001-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-09-20 | 2005-03-22 | 2005-09-21 | $7700.00 | Window Closed / Lapsed |